 IRVINE, CA, Sept. 01, 2021 GLOBE NEWSWIRE -- Odyssey Group International, Inc. OTC: ODYY the Company or Odyssey, a company focused on developing unique, life-saving medical products, today announced its approval to begin Phase 1 human clinical trials for drug candidate PRV-002 intended to treat concussions. The Companys Clinical Trial Protocol was approved by the Alfred Ethics Committee and allows for the immediate start of the human trial. 